NCT05813795View on ClinicalTrials.gov

A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity

PHASE3CompletedINTERVENTIONAL
Enrollment

664

Participants

Timeline

Start Date

April 5, 2023

Primary Completion Date

June 20, 2024

Study Completion Date

October 10, 2024

Conditions
Weight Management
Interventions
DRUG

Ecnoglutide Low Dosage

Subcutaneous Injection

DRUG

Ecnoglutide Medium Dosage

Subcutaneous Injection

DRUG

Ecnoglutide High Dosage

Subcutaneous Injection

DRUG

Placebo

Subcutaneous Injection with matched volume

Trial Locations (1)

Unknown

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Hangzhou Sciwind Biosciences Co., Ltd.

INDUSTRY